Tirdzniecība Ionis Pharmaceuticals, Inc. - IONS CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.04 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024068% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.001846% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 35.47 |
| Atvērt* | 35.15 |
| Izmaiņas par 1 gadu* | 1.03% |
| Dienas Diapazons* | 34.92 - 35.49 |
| 52 ned Diapazons | 31.46-48.82 |
| Vidējais apjoms (10 dienas) | 914.93K |
| Vidējais apjoms (3 mēneši) | 19.30M |
| Tirgus Kapitalizācija | 5.09B |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 142.95M |
| Ieņēmumi | 587.37M |
| EPS | -1.90 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 0.54 |
| Nākamās Peļņas Datums | May 2, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Mar 21, 2023 | 35.47 | 0.53 | 1.52% | 34.94 | 35.75 | 34.67 |
| Mar 20, 2023 | 35.45 | -0.31 | -0.87% | 35.76 | 36.04 | 35.03 |
| Mar 17, 2023 | 35.04 | 0.77 | 2.25% | 34.27 | 35.20 | 33.70 |
| Mar 16, 2023 | 34.86 | 1.50 | 4.50% | 33.36 | 35.00 | 33.36 |
| Mar 15, 2023 | 34.15 | 0.99 | 2.99% | 33.16 | 34.18 | 32.63 |
| Mar 14, 2023 | 33.74 | 0.43 | 1.29% | 33.31 | 33.88 | 32.39 |
| Mar 13, 2023 | 33.50 | 0.15 | 0.45% | 33.35 | 34.65 | 33.35 |
| Mar 10, 2023 | 33.91 | 0.05 | 0.15% | 33.86 | 34.75 | 33.52 |
| Mar 9, 2023 | 34.62 | -0.80 | -2.26% | 35.42 | 35.72 | 34.28 |
| Mar 8, 2023 | 35.62 | 0.12 | 0.34% | 35.50 | 35.83 | 35.15 |
| Mar 7, 2023 | 35.65 | -0.22 | -0.61% | 35.87 | 36.14 | 35.49 |
| Mar 6, 2023 | 36.12 | -0.10 | -0.28% | 36.22 | 36.63 | 35.81 |
| Mar 3, 2023 | 36.45 | 0.91 | 2.56% | 35.54 | 36.71 | 35.01 |
| Mar 2, 2023 | 35.66 | 0.39 | 1.11% | 35.27 | 35.84 | 35.07 |
| Mar 1, 2023 | 35.89 | 0.28 | 0.79% | 35.61 | 36.31 | 34.93 |
| Feb 28, 2023 | 35.71 | 0.62 | 1.77% | 35.09 | 36.58 | 34.60 |
| Feb 27, 2023 | 36.08 | 0.24 | 0.67% | 35.84 | 36.38 | 34.90 |
| Feb 24, 2023 | 35.56 | -0.50 | -1.39% | 36.06 | 36.16 | 35.25 |
| Feb 23, 2023 | 36.50 | 0.65 | 1.81% | 35.85 | 36.82 | 34.92 |
| Feb 22, 2023 | 36.74 | -1.03 | -2.73% | 37.77 | 38.21 | 35.46 |
Ionis Pharmaceuticals, Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 810.456 | 729.264 | 1122.6 | 599.674 | 514.179 |
| Ienākumi | 810.456 | 729.264 | 1122.6 | 599.674 | 514.179 |
| Cost of Revenue, Total | 10.842 | 11.947 | 4.384 | 1.82 | 0 |
| Bruto Peļņa | 799.614 | 717.317 | 1118.21 | 597.854 | 514.179 |
| Kopējie Darbības Izdevumi | 849.269 | 901.346 | 822.912 | 661.046 | 490.821 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 170.947 | 332.222 | 286.644 | 244.622 | 108.488 |
| Pētniecība un Attīstība | 634.953 | 526.877 | 465.688 | 414.604 | 374.644 |
| Neparedzēti Izdevumi (Ienākumi) | 32.527 | 30.3 | 66.196 | 0 | 7.689 |
| Darbības Izdevumi | -38.813 | -172.082 | 299.687 | -61.372 | 23.358 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 10.798 | 37.592 | 39.765 | -14.602 | -36.573 |
| Citi, Neto | -1.133 | -0.062 | -0.686 | -0.182 | -3.548 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -29.148 | -134.552 | 338.766 | -76.156 | -16.763 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -28.597 | -479.743 | 287.259 | -117.115 | 96.517 |
| Mazākuma Interese | 0 | 35.48 | -9.116 | 58.756 | 11.129 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -28.597 | -444.263 | 278.143 | -58.359 | 107.646 |
| Neto Ienākumi | -28.597 | -444.263 | 278.143 | 273.741 | 0.346 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -28.597 | -444.263 | 278.143 | -58.359 | 107.646 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -28.597 | -444.263 | 278.143 | 273.741 | 0.346 |
| Atšķaidīšanas Iestāstīšana | 0 | 0 | |||
| Atšķaidītie Neto Ienākumi | -28.597 | -444.263 | 278.143 | 273.741 | 0.346 |
| Atšķaidītie Ienākumi par Akcijām | 141.021 | 139.612 | 153.164 | 134.056 | 126.098 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.20279 | -3.18213 | 1.81598 | -0.43533 | 0.85367 |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.05286 | -3.04106 | 2.18246 | -0.43533 | 0.8933 |
| Ārkārtas Posteņi Kopā | 332.1 | -107.3 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 141.919 | 440.006 | 133.093 | 125.75 | 111.607 |
| Ienākumi | 141.919 | 440.006 | 133.093 | 125.75 | 111.607 |
| Cost of Revenue, Total | 4.17 | 2.226 | 3.079 | 2.958 | 2.578 |
| Bruto Peļņa | 137.749 | 437.78 | 130.014 | 122.792 | 109.029 |
| Kopējie Darbības Izdevumi | 199.423 | 219.401 | 218.942 | 207.346 | 203.578 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 34.127 | 37.6 | 31.093 | 56.455 | 61.199 |
| Pētniecība un Attīstība | 161.126 | 179.575 | 184.77 | 139.306 | 139.801 |
| Darbības Izdevumi | -57.504 | 220.605 | -85.849 | -81.596 | -91.971 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -6.754 | 4.788 | 2.545 | 1.237 | 2.229 |
| Citi, Neto | 0.187 | -0.477 | -0.469 | -0.189 | 0.003 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -64.071 | 224.916 | -83.773 | -80.548 | -89.739 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
| Mazākuma Interese | 0 | 0 | 0 | 0 | |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
| Neto Ienākumi | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
| Atšķaidītie Neto Ienākumi | -65.165 | 224.613 | -82.466 | -80.875 | -89.869 |
| Atšķaidītie Ienākumi par Akcijām | 141.599 | 141.21 | 141.139 | 140.962 | 140.77 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.46021 | 1.59063 | -0.58429 | -0.57374 | -0.63841 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.46021 | 1.59063 | -0.58429 | -0.53396 | -0.63841 |
| Neparedzēti Izdevumi (Ienākumi) | 0 | 0 | 8.627 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 2345.05 | 2130.71 | 2720.6 | 2207.89 | 1168.73 |
| Nauda un Īstermiņa Ieguldījumi | 2114.97 | 1892.38 | 2499.54 | 2084.07 | 1022.72 |
| Nauda un Ekvivalenti | 869.191 | 397.664 | 683.287 | 278.82 | 129.63 |
| Īstermiņa Ieguldījumi | 1245.78 | 1494.71 | 1816.26 | 1805.25 | 893.085 |
| Debitoru Parādu Kopsumma, Neto | 61.896 | 76.204 | 63.034 | 12.759 | 62.955 |
| Accounts Receivable - Trade, Net | 61.896 | 76.204 | 63.034 | 12.759 | 62.955 |
| Total Inventory | 24.806 | 21.965 | 18.18 | 8.582 | 9.982 |
| Other Current Assets, Total | 143.374 | 140.163 | 139.839 | 102.473 | 73.082 |
| Total Assets | 2611.69 | 2389.75 | 3233.11 | 2667.78 | 1322.77 |
| Property/Plant/Equipment, Total - Net | 196.069 | 181.077 | 166.251 | 132.16 | 121.907 |
| Property/Plant/Equipment, Total - Gross | 298.722 | 240.264 | 193.634 | 209.583 | |
| Accumulated Depreciation, Total | -102.653 | -74.013 | -61.474 | -87.676 | |
| Intangibles, Net | 29.005 | 27.937 | 25.674 | 24.032 | 22.004 |
| Other Long Term Assets, Total | 41.567 | 50.034 | 320.59 | 303.706 | 10.129 |
| Total Current Liabilities | 240.55 | 598.898 | 273.005 | 280.294 | 243.612 |
| Accounts Payable | 11.904 | 17.199 | 16.067 | 28.66 | 24.886 |
| Accrued Expenses | 129.97 | 155.889 | 106.152 | 77.629 | 91.769 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.926 | 316.11 | 13.749 | 1.621 | |
| Other Current Liabilities, Total | 97.75 | 109.7 | 150.786 | 160.256 | 125.336 |
| Total Liabilities | 1839.95 | 1646.47 | 1762.02 | 1619.7 | 1041.76 |
| Total Long Term Debt | 1228.02 | 623.529 | 770.3 | 632.971 | 605.856 |
| Long Term Debt | 1228.02 | 623.529 | 770.3 | 632.971 | 605.856 |
| Capital Lease Obligations | |||||
| Other Liabilities, Total | 371.379 | 424.046 | 505.26 | 567.359 | 108.026 |
| Total Equity | 771.737 | 743.282 | 1471.09 | 1048.08 | 281.013 |
| Common Stock | 0.141 | 0.14 | 0.14 | 0.138 | 0.125 |
| Additional Paid-In Capital | 1964.17 | 1895.52 | 2203.78 | 2047.25 | 1553.68 |
| Retained Earnings (Accumulated Deficit) | -1159.9 | -1131.31 | -707.534 | -967.293 | -1241.03 |
| Other Equity, Total | -32.668 | -21.071 | -25.29 | -32.016 | -31.759 |
| Total Liabilities & Shareholders’ Equity | 2611.69 | 2389.75 | 3233.11 | 2667.78 | 1322.77 |
| Total Common Shares Outstanding | 141.21 | 140.366 | 140.34 | 137.929 | 124.976 |
| Minority Interest | 213.453 | 139.081 | 84.267 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 2253.12 | 2345.05 | 2155.74 | 2238.42 | 1989.42 |
| Nauda un Īstermiņa Ieguldījumi | 2052.39 | 2114.97 | 1987.1 | 2059.27 | 1819.99 |
| Nauda un Ekvivalenti | 542.513 | 869.191 | 632.953 | 565.119 | 414.155 |
| Īstermiņa Ieguldījumi | 1509.88 | 1245.78 | 1354.15 | 1494.15 | 1405.84 |
| Debitoru Parādu Kopsumma, Neto | 26.122 | 61.896 | 9.068 | 24.004 | 23.397 |
| Accounts Receivable - Trade, Net | 26.122 | 61.896 | 9.068 | 24.004 | 23.397 |
| Total Inventory | 24.032 | 24.806 | 22.93 | 24.099 | 22.199 |
| Other Current Assets, Total | 150.577 | 143.374 | 136.643 | 131.045 | 123.827 |
| Total Assets | 2519.09 | 2611.69 | 2414.89 | 2497.07 | 2248.55 |
| Property/Plant/Equipment, Total - Net | 177.724 | 196.069 | 180.144 | 179.316 | 180.413 |
| Intangibles, Net | 29.295 | 29.005 | 30.038 | 29.373 | 28.795 |
| Other Long Term Assets, Total | 58.949 | 41.567 | 48.971 | 49.962 | 49.925 |
| Total Current Liabilities | 228.45 | 240.55 | 279.778 | 293.825 | 295.105 |
| Accounts Payable | 16.125 | 11.904 | 8.357 | 14.658 | 9.506 |
| Accrued Expenses | 115.781 | 129.97 | 108.001 | 105.372 | 108.029 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 4.206 | 0.926 | 65.045 | 69.848 | 69.504 |
| Other Current Liabilities, Total | 92.338 | 97.75 | 98.375 | 103.947 | 108.066 |
| Total Liabilities | 1809.52 | 1839.95 | 1884.36 | 1914.4 | 1567.99 |
| Total Long Term Debt | 1247.93 | 1228.02 | 1241.69 | 1240.7 | 870.916 |
| Long Term Debt | 1247.93 | 1228.02 | 1241.69 | 1240.7 | 870.916 |
| Other Liabilities, Total | 333.138 | 371.379 | 362.887 | 379.874 | 401.966 |
| Total Equity | 709.574 | 771.737 | 530.536 | 582.674 | 680.564 |
| Common Stock | 0.142 | 0.141 | 0.141 | 0.141 | 0.141 |
| Additional Paid-In Capital | 1983.08 | 1964.17 | 1942.35 | 1910.38 | 1925.8 |
| Retained Earnings (Accumulated Deficit) | -1225.07 | -1159.9 | -1384.52 | -1302.05 | -1221.18 |
| Other Equity, Total | -48.578 | -32.668 | -27.437 | -25.796 | -24.203 |
| Total Liabilities & Shareholders’ Equity | 2519.09 | 2611.69 | 2414.89 | 2497.07 | 2248.55 |
| Total Common Shares Outstanding | 141.753 | 141.21 | 141.184 | 141.022 | 140.924 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -28.597 | -479.743 | 287.259 | 214.985 | -10.783 |
| Nauda no Darbības | 30.799 | 35.892 | 345.627 | 602.906 | 174.149 |
| Nauda no Darbības | 15.487 | 13.365 | 12.54 | 10.706 | 6.708 |
| Amortization | 2.352 | 2.064 | 1.912 | 1.822 | 1.641 |
| Deferred Taxes | 0 | 341.729 | 0.911 | -290.516 | 0 |
| Bezskaidras Naudas Preces | 155.375 | 232.032 | 211.806 | 166.484 | 139.539 |
| Samaksātie Procenti Naudā | 4.778 | 6.247 | 9.87 | 9.592 | 8.035 |
| Izmaiņas Apgrozāmajā Kapitālā | -113.818 | -73.555 | -168.801 | 499.425 | 37.044 |
| Nauda no Ieguldījumu Darbībām | 194.906 | 274.477 | -41.274 | -929.563 | -358.291 |
| Kapitālie Izdevumi | -11.955 | -35.12 | -30.905 | -13.608 | -34.764 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 206.861 | 309.597 | -10.369 | -915.955 | -323.527 |
| Nauda no Darbībām ar Finansēšanu | 245.933 | -596.609 | 100.021 | 475.865 | 229.087 |
| Naudas Plūsma Finansēšanas Posteņos | -168.954 | -558.097 | -138.354 | 0 | 47.963 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 101.317 | -38.512 | 141.375 | 475.865 | 205.106 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 313.57 | 0 | 97 | 0 | -23.982 |
| Neto Izmaiņas Naudā | 471.527 | -285.623 | 404.467 | 149.19 | 44.945 |
| Cash Taxes Paid | 0.038 | 25.855 | 9.041 | 0 | |
| Ārvalstu Valūtas Ietekme | -0.111 | 0.617 | 0.093 | -0.018 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -65.165 | -28.597 | -253.21 | -170.744 | -89.869 |
| Cash From Operating Activities | -31.65 | 30.799 | -172.888 | -117.314 | -54.662 |
| Cash From Operating Activities | 3.701 | 15.487 | 11.665 | 7.951 | 3.917 |
| Amortization | 0.592 | 2.352 | 1.74 | 1.137 | 0.544 |
| Deferred Taxes | 0 | 0 | 0 | 0 | |
| Non-Cash Items | 32.983 | 155.375 | 125.535 | 88.261 | 43.346 |
| Cash Taxes Paid | 0.002 | 0.038 | 0.003 | 0.002 | |
| Cash Interest Paid | 0.594 | 4.778 | 3.527 | 2.866 | 0.594 |
| Changes in Working Capital | -3.761 | -113.818 | -58.618 | -43.919 | -12.6 |
| Cash From Investing Activities | -287.549 | 194.906 | 99.797 | -22.174 | 78.856 |
| Capital Expenditures | -2.705 | -11.955 | -9.453 | -6.13 | -1.772 |
| Other Investing Cash Flow Items, Total | -284.844 | 206.861 | 109.25 | -16.044 | 80.628 |
| Cash From Financing Activities | -7.325 | 245.933 | 308.423 | 306.965 | -7.577 |
| Financing Cash Flow Items | -9.173 | -168.954 | -168.43 | -167.966 | -15.337 |
| Issuance (Retirement) of Stock, Net | 1.848 | 101.317 | 101.316 | 99.394 | 7.76 |
| Foreign Exchange Effects | -0.154 | -0.111 | -0.043 | -0.022 | -0.126 |
| Net Change in Cash | -326.678 | 471.527 | 235.289 | 167.455 | 16.491 |
| Issuance (Retirement) of Debt, Net | 313.57 | 375.537 | 375.537 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Fidelity Management & Research Company LLC | Investment Advisor | 14.9052 | 21307519 | 16360 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.4574 | 13519789 | 736550 | 2022-12-31 | LOW |
| T. Rowe Price Investment Management, Inc. | Investment Advisor | 8.1692 | 11678259 | 521564 | 2022-12-31 | MED |
| Bellevue Asset Management AG | Investment Advisor | 6.8161 | 9743900 | 280500 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.986 | 7127720 | 135266 | 2022-12-31 | LOW |
| ClearBridge Investments, LLC | Investment Advisor/Hedge Fund | 3.7954 | 5425642 | -348250 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.9511 | 4218729 | 457774 | 2022-12-31 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 2.9049 | 4152607 | -508999 | 2022-12-31 | LOW |
| Tweedy, Browne Company LLC | Investment Advisor | 2.4771 | 3541136 | 818148 | 2022-12-31 | LOW |
| ARK Investment Management LLC | Investment Advisor | 1.8702 | 2673538 | -1039569 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.408 | 2012723 | 111580 | 2022-12-31 | LOW |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 1.3946 | 1993600 | 1224700 | 2022-12-31 | LOW |
| Camber Capital Management LP | Hedge Fund | 1.3466 | 1925000 | 0 | 2022-12-31 | MED |
| First Trust Advisors L.P. | Investment Advisor | 1.2458 | 1780933 | -296327 | 2022-12-31 | LOW |
| Macquarie Investment Management | Investment Advisor | 1.0435 | 1491687 | 657646 | 2022-12-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.907 | 1296647 | 465428 | 2022-12-31 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 0.8788 | 1256268 | 53922 | 2022-12-31 | LOW |
| Deep Track Capital LP | Hedge Fund | 0.8435 | 1205773 | 1205773 | 2022-12-31 | MED |
| Renaissance Technologies LLC | Hedge Fund | 0.8246 | 1178814 | 311100 | 2022-12-31 | HIGH |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.7966 | 1138714 | 15634 | 2022-12-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group500K+
Tirgotāji
92K+
Ikmēneša aktīvie klienti
$53M+
Ikmēneša ieguldījumu apjoms
$30M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Ionis Pharmaceuticals Company profile
Par Ionis Pharmaceuticals, Inc.
Uzņēmums Ionis Pharmaceuticals, Inc. nodarbojas ar ribonukleīnskābes (RNS) mērķterapiju atklāšanu un izstrādi. Uzņēmums galvenokārt koncentrējas uz sirds un asinsvadu un neiroloģijas franšīzēm. Tās produkti ir SPINRAZA, TEGSEDI un WAYLIVRA. SPINRAZA ir paredzēts visu vecumu pacientu ar muguras muskuļu atrofiju (SMA) - progresējošu, novājinošu un bieži letālu ģenētisku slimību - ārstēšanai. TEGSEDI ir paredzēts pacientu ar iedzimtas transtiretīna (TTR) izraisītu polineiropātiju, amiloidozi (hATTR), novājinošu, progresējošu un letālu slimību, ārstēšanai. WAYLIVRA ir antisense zāles, kas pieaugušiem pacientiem indicētas kā papildinājums diētai. Uzņēmuma III fāzes pētījumos ir vairāk nekā sešas zāles astoņām indikācijām, tostarp Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) un Tofersen (SOD1). Izstrādes stadijā ir kardiovaskulārās zāles Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen un IONIS-AGT-LRx.
| Industry: | Biotechnology & Medical Research (NEC) |
2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com